Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This phase I study will characterize the safety, tolerability, and maximum tolerated dose and
dose-limiting toxicity of weekly bolus Topotecan when administered in combination with to
different dosing regimens of docetaxel. We will also evaluate any anti-tumor activity of the
combination regimen.